Latest News

In the third and final part of our series on the challenge of institutional rigidity, we explore the exceptionalism in health technology decision-making, its implications for patients, and the most compelling argument for meaningful change, rooted in a 900-year-old principle.

A new Melbourne-based mental health clinic is hoping to transform approaches to addiction, depression, and trauma recovery by combining psychiatric care with innovative altered-state therapies.

In the second part of a series on the challenge of institutional rigidity, we discuss the need for stakeholders to shift their focus from the technical and procedural aspects of health technology decision-making to its power structures.

The collapse of the negotiation was set against the backdrop of US demands that countries like the UK pay higher prices for innovative prescription medicines.

Anatara Lifesciences (ASX:ANR) has announced the appointment of Dirk van Dissel as a Non-Executive Director, part of the company’s ongoing board renewal process.

CLINUVEL Pharmaceuticals (ASX:CUV) has announced it is advancing a new class of sustained-release liquid drug formulations into preclinical testing, marking the latest step in a decade-long investment in drug delivery research.

Alterity Therapeutics (ASXATH) has unveiled a new commercial assessment of its lead candidate ATH434, positioning the therapy as a potential first-in-class treatment for Multiple System Atrophy, a rare and debilitating Parkinsonian disorder with no approved therapies.

According to the 2024-25 Final Budget Outcome, PBS spending was impacted by "lower-than-estimated uptake of highly specialised medicines by patients, and lower-than-estimated utilisation of on-site pharmacists by residential aged care facilities."

Chimeric Therapeutics (ASX:CHM) has announced promising early results from its ongoing Phase 1/2 clinical trial of CHM CDH17, a novel third-generation CAR-T therapy targeting gastrointestinal cancers.

Australians living with severe atopic dermatitis have been handed yet another stark reminder of the realities of PBS decision-making.

There is no underlying genius to the decision-making. Any reputation for sophistication masks a blunt and straightforward reality. The technical underpinnings mask systems characterised by immense power asymmetry.

Health Minister Mark Butler has announced four PBS listings for 1 October, including AstraZeneca's TRUQAP (capivasertib) for a form of breast cancer.